Printer Friendly

Articles from Stem Cell Business News (February 20, 2017)

1-9 out of 9 article(s)
Title Author Type Words
Biostage closes $8m public offering. 121
Biotime licenses retinal disease therapy from Pitt. 163
Blood test could determine whether patients will benefit from stem cell transplant. 657
Cellect files for delisting from Tel Aviv Stock Exchange. 153
Company launches naive stem cell culture system. 184
Last subject enrolled in phase 2 trial for major depressive disorder. Clinical report 163
Low rheumatoid arthritis activity over nine months after cell therapy. Clinical report 1061
More than 80 percent of new CRISPR users are first-time gene editors. 162
Software suite created for single-cell RNA-seq data analysis, visualization. 316

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters